Remarkable Effect of Gefitinib Retreatment in a Lung Cancer Patient With Lepidic Predominat Adenocarcinoma Who Had Experienced Favorable Results From Initial Treatment With Gefitinib: A Case Report
Su Jin Lee, Ho Sung Lee, Jae Sung Choi, Ju Ock Na, Ki Hyun Seo, Mi Hye Oh, Sung Shick Jou
Abstract
Gefitnib is an oral agent of epidermal growth factor receptor tyrosine kinase inhibitor, and it has a certain efficacy against non-small cell lung cancer. There are some reports that the non-small cell lung cancer patients who experienced disease progression after responding to gefitinib were again sensitive to re-administration of gefitinib following temporary cessation of gefitinib. This is the case report showing a remarkable effect of gefitinib re-treatment in a patient with metastatic invasive adenocarinoma who had experienced favorable results from the initial treatment with gefitinib.
doi:10.4021/jocmr816e
Keywords
Gefitinib; Retreatment; Lepidic predominant adenocarcinoma
Full Text:
HTML
PDF